🚨⭐🟠 #ESMO26 | Day 2 | Abstract 4741RO | NIAGARA

Exploratory Analysis of Molecular Subtypes and Association With Treatment Outcomes in Muscle-Invasive Bladder Cancer

🎤 Excellent presentation by @MattGalsky 🇺🇸
@OncoAlert @myESMO

🧬 Does tumor biology influence the benefit of perioperative durvalumab in MIBC?

🔬 STUDY DESIGN

Phase III NIAGARA | N=1,063

Perioperative durvalumab + neoadjuvant gemcitabine/cisplatin vs chemotherapy alone, followed by radical cystectomy.

Exploratory molecular analysis:
✅ Whole-exome sequencing: n=407
✅ RNA sequencing: n=402

📊 KEY MOLECULAR FINDINGS

🔹 Broad EFS benefit: Durvalumab-containing treatment favored EFS across multiple mutation-defined subgroups.

🔹 Genomic alterations: Greater apparent benefit was observed in tumors harboring TP53 or FGFR3 mutations, cell-cycle or RTK/RAS/PI3K pathway alterations, and high tumor mutational burden.

🔹 Basal-squamous subtype: Showed one of the strongest exploratory signals of benefit, with increased immune-infiltration signatures.

🔹 Luminal-papillary subtype: The EFS benefit appeared less evident than in other transcriptomic subtypes.

⚠️ These findings are exploratory. No molecular subtype has been prospectively validated to predict differential benefit from perioperative durvalumab.

⭐ MY POINT OF VIEW | CLINICAL PEARL

Molecular heterogeneity may influence the magnitude of benefit, but it should not yet determine who receives potentially curative perioperative immunotherapy.

🧬 The real opportunity is moving from molecular classification toward clinically validated predictive biomarkers.

💡 The future is not simply knowing the tumor subtype—it is knowing how to act on it without compromising cure.

Congratulations to @MattGalsky and the NIAGARA investigators for this insightful translational analysis!

@urologysummit @gbanna74 @ravikanesvaran @Uromigos @LosUromigos

@tompowles1 @PGrivasMDPhD @apolo_andrea @AndreaNecchi @sonpavde @drenriquegrande @montypal

@ecancer @UrologyTimes @urotoday @wearemedsir @OpenMedicineHQ

#BladderCancer #MIBC #GUOncology #PrecisionOncology #Biomarkers